Advertisement
Advertisement
Trending on Urology Times
1
Datopotamab deruxtecan enters phase 3 trial in high-risk muscle-invasive urothelial cancer
2
Defining High-Risk NMIBC and Diagnostic Gaps Before Referral
3
Pearls & Perspectives: From Emergency Medicine to Sexual Medicine, With Jeff Myers, DO
4
Nicole L. Miller, MD, FACS, on persistent LUTS after BPH treatment
5